Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data

Hjelmgren, Jonas; Svensson, Åke; Jørgensen, Eric; Lindemalm-Lundstam, B; Tennvall, Gunnel Ragnarson

doi:10.1111/j.1365-2133.2006.07707.x

Cited by 21 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The variety of interventions considered were relatively limited when compared with the 240 intervention groups listed on the GREAT database. Of the studies found within this review, the most commonly evaluated intervention types were topical calcineurin inhibitors (n = 14), [15][16][17][18][19][20][21][22][23][24][25][26][27][28] followed by infant formula feeds intended to prevent eczema from developing (n = 10). [29][30][31][32][33][34][35][36][37][38] Six studies evaluated a change of service delivery, including the use of web-based consultations, 39 delivering care by a nurse practitioner, [40][41][42] the development of a paediatric dermatology service (although what this entailed was not described) 43 and the use of interdisciplinary group sessions with an educational counterpart.…”

Section: Resultsmentioning

confidence: 99%

Understanding economic evidence for the prevention and treatment of atopic eczema

2019

View full text Add to dashboard Cite

Summary Background Atopic eczema is an inflammatory skin condition, with a similar impact on health‐related quality of life as other chronic diseases. Increasing pressures on resources within the National Health Service increase the importance of having good economic evidence to inform their allocation. Objectives To educate dermatologists about economic methods with reference to currently available economic evidence on eczema. Methods The role of different types of economic evidence is illustrated by evidence found in a systematic literature search conducted across 12 online databases up to 22 May 2017. Primary empirical studies either reporting the results of a cost‐of‐illness study or evaluating the cost, utility or full economic evaluation of interventions for preventing or treating eczema were included. Two reviewers independently assessed studies for eligibility and performed data abstraction, with disagreements resolved by a third reviewer. Evidence tables of results were produced for narrative discussion. The reporting quality of economic evaluations was assessed. Results Seventy‐eight studies (described in 80 papers) were deemed eligible. Thirty‐three (42%) were judged to be economic evaluations, 12 (15%) cost analyses, six (8%) utility analyses, 26 (33%) cost‐of‐illness studies and one a feasibility study (1%). The calcineurin inhibitors tacrolimus and pimecrolimus, as well as barrier creams, had the most economic evidence available. Partially hydrolysed infant formula was the most commonly evaluated prevention. Conclusions The current level of economic evidence for interventions aimed at preventing and treating eczema is limited compared with that available for clinical outcomes, suggesting that greater collaboration between clinicians and economists might be beneficial.

show abstract

Section: Resultsmentioning

confidence: 99%

Understanding economic evidence for the prevention and treatment of atopic eczema

2019

View full text Add to dashboard Cite

show abstract

“…The DLQI and CDLQI have been the most frequently used, and the IDQoL and DFI are the most widely used AD‐specific and infant and family QoL instruments. In some clinical trials, ‘study‐specific’ nonvalidated instruments were used . Reports of other trials do not contain information on which HRQoL instruments were used …”

Section: Resultsmentioning

confidence: 99%

Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life

Chernyshov

Tómas-Aragonés

Manolache³

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

There is a need for researchers to have easy reference to the wide spectrum of different types of quality of life (QoL) instruments that can be used in atopic dermatitis (AD). Previous reviews on QoL in AD do not cover the full spectrum of QoL measures used in studies on AD. This study, on behalf of the European Academy of Dermatology and Venereology (EADV) Task Force on QoL, contains information on instruments available for health-related QoL and family QoL assessment in AD including information on validation, experience of QoL assessment in AD for different purposes, peculiarities of QoL assessment in different age groups, expert analysis of available instruments including data on limitations of their use and recommendations of the Task Force.

show abstract

“…Table 1 in the above mentioned article 1 , was incorrectly published. The data should have been presented as follows:…”

Section: Transition Probabilities During 3‐week Cycles For Patients mentioning

confidence: 99%

Corrigendum

2008

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data

Cited by 21 publications

References 15 publications

Understanding economic evidence for the prevention and treatment of atopic eczema

Understanding economic evidence for the prevention and treatment of atopic eczema

Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life

Corrigendum

Contact Info

Product

Resources

About